Cat. #153541
Anti-Sufu
Cat. #: 153541
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Sufu (UniProt ID: Q9UMX1)
Class: Polyclonal
Application: WB
Reactivity: Human ; Mouse
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Vincenzo D'Angiolella
Institute: University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Sufu
- Alternate name: Suppressor of fused homolog, SUFUH
- Research fields: Cancer;Developmental biology;Genetics
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Cell signalling pathway: Hedgehog
- Reactivity: Human ; Mouse
- Host: Rabbit
- Application: WB
- Description: Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
- Immunogen: Sufu peptide: Hu #347~360: CLESDSSTAIIPHEL (non-phosphorylated)
Target Details
- Target: Sufu (UniProt ID: Q9UMX1)
- Target background: Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
Applications
- Application: WB
Handling
- Format: Liquid
- Concentration: 2 mg/ml
- Unit size: 100 ug
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-phospho-Sufu, Polyclonal
